MBRX

Moleculin Biotech, Inc. (MBRX) | Rumor.io

Moleculin Biotech

MBRX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,118

Bullish sentiment (50-day avg)76%

Price to earnings ratio0.04

Market capitalization11.6M

Earnings per share14.6

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-33.6M

Social

What share of all stock conversation is about MBRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 25

Moleculin Biotech's lead drug candidate, Annamycin, has shown antitumor activity in pancreatic cancer models, with data indicating that its antitumor activity is partially mediated by CD8+ T cell cytotoxicity.
The preclinical data presented at the AACR Conference on Pancreatic Cancer suggest a potential immune-mediated mechanism alongside Annamycin's direct cytotoxic activity, supporting a promising therapeutic approach.
Annamycin has demonstrated significant tumor inhibition and a >60% improvement in median survival (29 vs 18 days) in pancreatic cancer models, with its antitumor activity linked to CD8+ T cell cytotoxicity.

Generated by AI

Sentiment

Of the messages about MBRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	77.78% +11.11	82.35% +12.62	59.53% -16.08
Bearish	—	22.22% -11.11	17.65% -12.62	40.47% +16.08

Bullish· Nov 3

Moleculin Biotech, Inc. ($MBRX) has huge upside potential, with interim results expected soon and a possible price target of $10.
Swedish investors are now participating in $MBRX, which could be a significant trigger for the stock.
$MBRX is undervalued and has the potential to reach $3 or more, with the stock already doubling in value at current levels.

Bearish· Jul 31

The company's financial situation is precarious, with a 62% drop in stock price after filing its S-1 and a mention of "runway into Q3 2026".
The company's management is accused of front-loading a scam, diluting the stock to raise valuation, and making decisions that are "out of their fuckn mind".
The stock is experiencing a "death spiral" with a potential hard bounce, and investors are at risk of significant losses, with some already down $2000.

Generated by AI

Topics

Of the messages about MBRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	94.74%	98.25%	77.77%
Analysts	—	0%	0%	7.55%
Controversies	—	0%	0%	0.31%
Technical Analysis	—	5.26%	1.75%	8.17%
Macro	—	0%	0%	6.2%
Earnings	—	0%	0%	0%

Announcements· Apr 23

Moleculin Biotech's Annamycin extended median survival by more than 60% in metastatic pancreatic cancer preclinical models.
Annamycin demonstrated significant tumor volume reduction across multiple PDAC models, including orthotopic human and syngeneic systems.
Annamycin showed superior accumulation compared to standard chemotherapy and did not exhibit cardiotoxicity, a limitation of conventional anthracyclines.

Technical Analysis· Aug 27

The stock has shown solid momentum with increasing volume and strong price action, up 3.98% from an early rally under $0.66.
Technical analysis suggests a potential continuation of the upward trend if buyers remain supportive.
Key levels of interest include the $0.60 break, the pre-market high, and the target price of $0.63.

Generated by AI

Community

Of the messages about MBRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	69.05%	59.26%	38.86%
Newcomers	0%	30.95%	40.74%	61.14%

Regulars· Sep 25

Moleculin Biotech's lead drug candidate, Annamycin, has shown promising results in preclinical data presented at the AACR26 Conference, indicating its antitumor activity is partially mediated by CD8+ T cell cytotoxicity in pancreatic cancer.
The new findings suggest a potential immune-mediated mechanism alongside Annamycin's direct cytotoxic activity, which could have significant implications for the treatment of pancreatic cancer.
Moleculin Biotech's preclinical data has been well-received by the medical community, with several researchers and investors expressing enthusiasm for the company's progress in developing an effective treatment for this aggressive form of cancer.

Newcomers· Aug 27

The CEO and CFO of Moleculin Biotech, Inc. (MBRX) invested $620,000 of their own money into the company at $0.75, suggesting they have faith in the company's future.
The MIRACLE trial is expected to enroll 90 patients by September, and the company is on track to deliver strong data, which could lead to a significant increase in the stock price.
The company has a partnership on the way and has secured $9.3 million in financing, which extends its runway until the MIRACLE trial catalyst is realized, providing a strong setup for a potential explosion in the stock price.

Generated by AI

Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity HOUSTON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company's global intellectual property portfolio protecting its proprietary lung-targeted liposom

6d agoYahoo Finance

Moleculin Biotech receives Nasdaq delisting notice after minimum bid price violation

11d agoInvesting.com

Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific venues in September 2026, including the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer

16d agoYahoo Finance

Moleculin Biotech at H.C. Wainwright conference: aml hope builds

18d agoInvesting.com

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

18d agoYahoo Finance

Also Discussed

Investors talking about MBRX also mention

#	Name	Attention
1	Delcath Systems, Inc.DCTH	0%new
2	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
3	Eltek Ltd.ELTK	0%new
4	Bio-Path Holdings Inc.BPTH	0%0
5	Pulmatrix Inc.PULM	0%0
6	AVGR - Avinger, Inc.	——
7	Xtant Medical Holdings Inc.XTNT	0%0
8	Precipio Inc.PRPO	0%0
9	Capricor Therapeutics, Inc.CAPR	0.34%+0.25
10	AEZS - Aeterna Zentaris Inc.	——

Moleculin Biotech, Inc.

Healthcare
Biotechnology

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for hard-to-treat cancers and viral infections. Its current pipeline centers on Annamycin, an anthracycline-based candidate being evaluated in combination regimens for relapsed or refractory acute myeloid leukemia and other tumor indications, including soft tissue sarcoma lung metastases. The company also advances programs aimed at difficult viral diseases, reflecting a broader approach to unmet medical needs in oncology and virology. Moleculin Biotech works as a specialty drug developer, with research and clinical operations designed to move product candidates through late-stage development and regulatory review. Based in Houston, Texas, the company occupies a niche position in the biopharmaceutical market, where it contributes experimental treatment options for conditions with limited current therapies.

Website

Location

5300 Memorial Drive

Houston, TX, 77007

United States

Social

What share of all stock conversation is about MBRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 25

Moleculin Biotech's lead drug candidate, Annamycin, has shown antitumor activity in pancreatic cancer models, with data indicating that its antitumor activity is partially mediated by CD8+ T cell cytotoxicity.
The preclinical data presented at the AACR Conference on Pancreatic Cancer suggest a potential immune-mediated mechanism alongside Annamycin's direct cytotoxic activity, supporting a promising therapeutic approach.
Annamycin has demonstrated significant tumor inhibition and a >60% improvement in median survival (29 vs 18 days) in pancreatic cancer models, with its antitumor activity linked to CD8+ T cell cytotoxicity.

Generated by AI

Sentiment

Of the messages about MBRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	77.78% +11.11	82.35% +12.62	59.53% -16.08
Bearish	—	22.22% -11.11	17.65% -12.62	40.47% +16.08

Bullish· Nov 3

Moleculin Biotech, Inc. ($MBRX) has huge upside potential, with interim results expected soon and a possible price target of $10.
Swedish investors are now participating in $MBRX, which could be a significant trigger for the stock.
$MBRX is undervalued and has the potential to reach $3 or more, with the stock already doubling in value at current levels.

Bearish· Jul 31

The company's financial situation is precarious, with a 62% drop in stock price after filing its S-1 and a mention of "runway into Q3 2026".
The company's management is accused of front-loading a scam, diluting the stock to raise valuation, and making decisions that are "out of their fuckn mind".
The stock is experiencing a "death spiral" with a potential hard bounce, and investors are at risk of significant losses, with some already down $2000.

Generated by AI

Topics

Of the messages about MBRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	94.74%	98.25%	77.77%
Analysts	—	0%	0%	7.55%
Controversies	—	0%	0%	0.31%
Technical Analysis	—	5.26%	1.75%	8.17%
Macro	—	0%	0%	6.2%
Earnings	—	0%	0%	0%

Announcements· Apr 23

Moleculin Biotech's Annamycin extended median survival by more than 60% in metastatic pancreatic cancer preclinical models.
Annamycin demonstrated significant tumor volume reduction across multiple PDAC models, including orthotopic human and syngeneic systems.
Annamycin showed superior accumulation compared to standard chemotherapy and did not exhibit cardiotoxicity, a limitation of conventional anthracyclines.

Technical Analysis· Aug 27

The stock has shown solid momentum with increasing volume and strong price action, up 3.98% from an early rally under $0.66.
Technical analysis suggests a potential continuation of the upward trend if buyers remain supportive.
Key levels of interest include the $0.60 break, the pre-market high, and the target price of $0.63.

Generated by AI

Community

Of the messages about MBRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	69.05%	59.26%	38.86%
Newcomers	0%	30.95%	40.74%	61.14%

Regulars· Sep 25

Moleculin Biotech's lead drug candidate, Annamycin, has shown promising results in preclinical data presented at the AACR26 Conference, indicating its antitumor activity is partially mediated by CD8+ T cell cytotoxicity in pancreatic cancer.
The new findings suggest a potential immune-mediated mechanism alongside Annamycin's direct cytotoxic activity, which could have significant implications for the treatment of pancreatic cancer.
Moleculin Biotech's preclinical data has been well-received by the medical community, with several researchers and investors expressing enthusiasm for the company's progress in developing an effective treatment for this aggressive form of cancer.

Newcomers· Aug 27

The CEO and CFO of Moleculin Biotech, Inc. (MBRX) invested $620,000 of their own money into the company at $0.75, suggesting they have faith in the company's future.
The MIRACLE trial is expected to enroll 90 patients by September, and the company is on track to deliver strong data, which could lead to a significant increase in the stock price.
The company has a partnership on the way and has secured $9.3 million in financing, which extends its runway until the MIRACLE trial catalyst is realized, providing a strong setup for a potential explosion in the stock price.

Generated by AI

Moleculin Biotech

Social

Sep 25

Bullish· Nov 3

Bearish· Jul 31

Announcements· Apr 23

Technical Analysis· Aug 27

Regulars· Sep 25

Newcomers· Aug 27

Moleculin receives Mexican patent for Annamycin formulation

Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

Moleculin Biotech receives Nasdaq delisting notice after minimum bid price violation

Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

Moleculin Biotech at H.C. Wainwright conference: aml hope builds

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

Also Discussed

Moleculin Biotech, Inc.

Company Information

Location

Moleculin receives Mexican patent for Annamycin formulation

Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

Moleculin Biotech receives Nasdaq delisting notice after minimum bid price violation

Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

Moleculin Biotech at H.C. Wainwright conference: aml hope builds

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

Also Discussed

Social

Sep 25

Bullish· Nov 3

Bearish· Jul 31

Announcements· Apr 23

Technical Analysis· Aug 27

Regulars· Sep 25

Newcomers· Aug 27